GS
LABD icon

GTS Securities’s Direxion Daily S&P Biotech Bear 3X ETF LABD Stock Holding History

GTS Securities’s Portfolio LABD Stock Details LABD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,240
Closed -$72.4K – 2789
2024
Q3 		$72.4K Sell
1,240
-2,590
-68% -$157K ﹤0.01% 3849
2024
Q2 		$281K Buy
3,830
+180
+5% +$15.2K ﹤0.01% 3184
2024
Q1 		$266K Buy
3,650
+980
+37% +$81.8K ﹤0.01% 3100
2023
Q4 		$259K Sell
2,670
-350
-12% -$68.1K ﹤0.01% 3342
2023
Q3 		$622K Buy
+3,020
New +$491K ﹤0.01% 2405

Other funds holding LABD

BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
JF
Jump Financial Chicago, Illinois $12.4B AUM 62.79% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

GTS Securities's LABD Position: Q2 2026 in Review

GTS Securities increased its Direxion Daily S&P Biotech Bear 3X ETF (LABD) stake by 81% in Q2 2026, buying an estimated $461K and bringing the position to 76,580 shares worth $590K. The position accounts for 0.01% of the portfolio, ranked #638.

GTS Securities first reported a position in LABD in Q2 2023 and has held it in 11 quarters since. The position peaked at $966K in Q3 2023. 21 funds tracked by Wall St. Rank hold LABD as of Q2 2026.

  • GTS Securities held 76,580 shares of Direxion Daily S&P Biotech Bear 3X ETF worth $590K as of Q2 2026.
  • GTS Securities bought 34,219 Direxion Daily S&P Biotech Bear 3X ETF shares in Q2 2026, an estimated $461K.
  • Direxion Daily S&P Biotech Bear 3X ETF made up 0.01% of GTS Securities's portfolio in Q2 2026, its #638 holding.
  • GTS Securities first reported a position in Direxion Daily S&P Biotech Bear 3X ETF in Q2 2023 and has held it in 11 quarters since.
  • GTS Securities's Direxion Daily S&P Biotech Bear 3X ETF position peaked at $966K in Q3 2023.
  • 21 funds tracked by Wall St. Rank held Direxion Daily S&P Biotech Bear 3X ETF as of Q2 2026.

Based on GTS Securities's 13F filing for Q2 2026, filed 14 Aug 2026.